SILVER SPRING, Md.,
Sept. 26, 2013 /PRNewswire/ --
Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen")
announces that Clotamin® is now available in over 3000 retail CVS
locations. Clotamin® is a unique and complete multivitamin
formulated without vitamin k to meet the special nutritional needs
of people taking blood thinning medications (anticoagulants) such
as Warfarin. Because it does not contain vitamin k,
Clotamin® can be taken with Warfarin without affecting
international normalized ratio (INR) levels. Warfarin is the most
prescribed blood thinning medication in North America and is also known under the
brand names of Coumadin®, Jantoven®,
Marevan®, and Waran®. Warfarin therapy
reduces the formation of blood clots, which is important in the
prevention of heart attacks, strokes, and blockage of major veins
and arteries.
About Pharmagen
Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and
operating divisions Pharmagen Laboratories, Inc., Pharmagen
Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader
in innovative solutions to the nations sterile pharmaceutical
crisis. With a multifaceted approach, Pharmagen is meeting the
demand of health provider market through dynamic, independent
wholesale, compounding, and innovative IT solutions.
Nationally focused, Pharmagen is a dynamic distributor of specialty
drugs, compounding and admix pharmacy and producer of
over-the-counter ("OTC") branded multivitamins to the healthcare
provider market. Pharmagen currently functions as a just-in-time
source of supply for hospitals for those products that are
hard-to-find due to drug manufacturers' production shortages.
Contact: 888-264-4597 or info@pharmagenrx.com
Safe Harbor Statement
Information in this document
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "forecast", "anticipate", "estimate", "project",
"intend", "expect", "should", "believe", and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements involve, and are subject to known and
unknown risks, uncertainties and other factors which could cause
Pharmagen actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in Pharmagen' filings with the
U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Pharmagen herein are expressly qualified
in their entirety by the above-mentioned cautionary statement.
Pharmagen disclaims any obligation to update forward-looking
statements contained in this estimate, except as may be required by
law.
SOURCE Pharmagen, Inc.